Trial Profile

Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Letrozole (Primary)
Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
Focus Therapeutic Use

Most Recent Events

24 Feb 2025 Status changed to discontinued.
15 Aug 2023 Planned End Date changed from 15 Jun 2024 to 15 Jun 2025.
15 Aug 2023 Planned primary completion date changed from 15 Jun 2023 to 15 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com